These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17095524

  • 1. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [Abstract] [Full Text] [Related]

  • 2. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A.
    Cancer Invest; 2005 May 01; 23(8):665-70. PubMed ID: 16377584
    [Abstract] [Full Text] [Related]

  • 4. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

  • 5. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
    Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulias V, Mavroudis D.
    Oncology; 2006 Aug 01; 71(3-4):190-6. PubMed ID: 17641537
    [Abstract] [Full Text] [Related]

  • 6. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):847-53. PubMed ID: 17609947
    [Abstract] [Full Text] [Related]

  • 7. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.
    Jpn J Clin Oncol; 2008 Nov 01; 38(11):777-85. PubMed ID: 18927230
    [Abstract] [Full Text] [Related]

  • 8. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.
    Jpn J Clin Oncol; 2010 Aug 01; 40(8):732-8. PubMed ID: 20430774
    [Abstract] [Full Text] [Related]

  • 9. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S.
    Oncology; 2005 Aug 01; 69(6):463-9. PubMed ID: 16374040
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
    Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA.
    Am J Clin Oncol; 2011 Feb 01; 34(1):27-31. PubMed ID: 20142723
    [Abstract] [Full Text] [Related]

  • 11. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):695-702. PubMed ID: 17549475
    [Abstract] [Full Text] [Related]

  • 12. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP.
    Clin Cancer Res; 2002 Feb 01; 8(2):413-8. PubMed ID: 11839657
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C.
    Anticancer Drugs; 2008 Jun 01; 19(5):541-5. PubMed ID: 18418221
    [Abstract] [Full Text] [Related]

  • 14. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F.
    Oncology; 2009 Jun 01; 76(1):49-54. PubMed ID: 19039248
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
    Harrison LE, Bryan M, Pliner L, Saunders T.
    Ann Surg Oncol; 2008 May 01; 15(5):1407-13. PubMed ID: 18157576
    [Abstract] [Full Text] [Related]

  • 16. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.
    Gynecol Oncol; 2009 Aug 01; 114(2):219-24. PubMed ID: 19446868
    [Abstract] [Full Text] [Related]

  • 17. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.
    Am J Clin Oncol; 2006 Jun 01; 29(3):267-75. PubMed ID: 16755180
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.
    Gonçalves A, Braud AC, Viret F, Genre D, Gravis G, Tarpin C, Giovannini M, Maraninchi D, Viens P.
    Anticancer Res; 2003 Jun 01; 23(4):3543-8. PubMed ID: 12926104
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.
    Am J Clin Oncol; 2008 Oct 01; 31(5):476-80. PubMed ID: 18838885
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
    Airoldi M, Cattel L, Milla P, Pedani F, Garzaro M, Dosio F.
    Anticancer Res; 2008 Oct 01; 28(4C):2519-27. PubMed ID: 18751444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.